Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria

DOI: https://doi.org/10.1056/nejmc2404445

IF: 158.5

2024-06-07

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 390, Issue 21, Page 2032-2034, June 6, 2024.

medicine, general & internal

What problem does this paper attempt to address?

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria

Régis Peffault de Latour,Alexander Röth,Austin G Kulasekararaj,Bing Han,Phillip Scheinberg,Jaroslaw P Maciejewski,Yasutaka Ueda,Carlos M de Castro,Eros Di Bona,Rong Fu,Li Zhang,Morag Griffin,Saskia M C Langemeijer,Jens Panse,Hubert Schrezenmeier,Wilma Barcellini,Vitor A Q Mauad,Philippe Schafhausen,Suzanne Tavitian,Eloise Beggiato,Lee Ping Chew,Anna Gaya,Wei-Han Huang,Jun Ho Jang,Toshio Kitawaki,Abdullah Kutlar,Rosario Notaro,Vinod Pullarkat,Jörg Schubert,Louis Terriou,Michihiro Uchiyama,Lily Wong Lee Lee,Eng-Soo Yap,Flore Sicre de Fontbrune,Luana Marano,Ferras Alashkar,Shreyans Gandhi,Roochi Trikha,Chen Yang,Hui Liu,Richard J Kelly,Britta Höchsmann,Cécile Kerloeguen,Partha Banerjee,Rafael Levitch,Rakesh Kumar,Zhixin Wang,Christine Thorburn,Samopriyo Maitra,Shujie Li,Aurelie Verles,Marion Dahlke,Antonio M Risitano,Austin G. Kulasekararaj,Jaroslaw P. Maciejewski,Carlos M. de Castro,Saskia M.C. Langemeijer,Vitor A.Q. Mauad,Richard J. Kelly,Antonio M. Risitano

DOI: https://doi.org/10.1056/nejmoa2308695

IF: 158.5

2024-03-15

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 390, Issue 11, Page 994-1008, March 2024.

medicine, general & internal
Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria

Carlos M. de Castro,Bhumika J. Patel

DOI: https://doi.org/10.1080/14656566.2024.2404110

2024-10-17

Expert Opinion on Pharmacotherapy

Abstract:Introduction Standard-of-care first-line treatments for paroxysmal nocturnal hemoglobinuria (PNH) include the anti-C5 therapies eculizumab and ravulizumab. However, persistent anemia, likely due to extravascular hemolysis, and reduced quality of life (QoL) due to frequent infusions remain concerns. Iptacopan is a first-in-class oral proximal complement inhibitor that targets factor B in the alternative pathway (upstream of C5), limiting intravascular and extravascular hemolysis.

pharmacology & pharmacy
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria

Satoko Ito,Karthik Chetlapalli,Daniel Wang,Kunal C Potnis,Rhys Richmond,Harlan Krumholz,Alfred I Lee,Adam Cuker,George Goshua

DOI: https://doi.org/10.1182/blood.2024025176

IF: 20.3

2024-10-08

Blood

Abstract:Iptacopan, a novel oral Factor B inhibitor, recently obtained FDA approval for treating paroxysmal nocturnal hemoglobinuria, a rare blood disorder characterized by persistent complement-mediated hemolytic anemia. The standard-of-care (SOC) has traditionally relied on complement C5 inhibitors eculizumab and ravulizumab, which are limited by persistent anemia from extravascular hemolysis and requirement for intravenous infusion. Recent publication of phase 3 studies in this arena reinforces...

hematology
Iptacopan Efficacy and Safety to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta-Analysis

Ibrahim M Dighriri,Reham M Al-Qahtani,Amal O Almutairi,Rahaf N Alhashbari,Hanin A Kanbeja,Salman A AlOjaimi,Mona A Aljuaid,Abdullah A Albaradi,Sahar T Almanjumi,Samah A Alqurashi,Maryam S Majrashi,Hatoon M Alansari,Ghayah A Jabbari,Abdulaziz S Alharbi,Amnah A Alnami

DOI: https://doi.org/10.7759/cureus.67830

2024-08-26

Cureus

Abstract:Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon blood condition caused by complement-mediated hemolysis. In early clinical studies, iptacopan, an oral factor B inhibitor, showed promise in treating PNH. This systematic review aimed to compile information on the effectiveness and safety of iptacopan for PNH. A systematic review was performed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards. The Medline, Embase, PubMed, and Cochrane Central databases were searched for randomized controlled trials (RCTs) and observational studies that evaluated iptacopan for PNH. The primary efficacy outcomes were hemoglobin and lactate dehydrogenase (LDH) changes. A fixed-effects model was used for the meta-analysis. Six studies (three prospective cohorts, two RCTs, and one non-randomized trial) were included, comprising 197 patients. Iptacopan therapy significantly increased hemoglobin levels (mean differences (MD) = 12.98 g/L; 95% CI: 11.82-14.13; p < 0.0001) and decreased LDH (MD = -83.55 IU/L; 95% CI: -83.77 to -83.34; p < 0.0001). Subgroup analyses revealed more significant hemoglobin increases in European vs. Asian populations, studies with baseline Hb > 10 g/dL vs. < 10 g/dL, and studies lasting > 24 weeks vs. ≤ 24 weeks. LDH decreases were more pronounced in studies with baseline LDH > 500 IU/L vs. < 500 IU/L. The incidence of adverse events ranged from 66% to 90%, with the most common being headache, nasopharyngitis, and diarrhea. Serious adverse events occurred in 0-20% of patients across studies. Only one patient withdrew because adverse effects were reported across all studies. Preliminary data support iptacopan's effectiveness in improving hemoglobin levels and lowering hemolysis in PNH, both as a monotherapy and in combination with usual treatment. The safety profile appears to be excellent, with a minimal incidence of major adverse events and treatment discontinuation. Further studies are needed to validate the effectiveness and safety of larger, longer-term trials. Iptacopan is a viable oral therapy option for PNH.
Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH)

Wolfgang Füreder,Renate Thalhammer,Peter Valent

DOI: https://doi.org/10.1007/s00508-024-02390-w

Abstract:Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematologic disorder characterized by a loss of glycosyl-phosphatidyl-inositol-linked (GPI) proteins on various hematopoietic cells. Some GPI proteins are involved in the regulation of the complement system, and their absence renders erythrocytes susceptible to complement-mediated lysis. Current standard of care in PNH is to block the complement system at the level of C5 using ravulizumab or eculizumab; however, some patients with PNH may develop extravascular hemolysis (EVH) during treatment with C5 inhibitors. The proximal complement inhibitor iptacopan has recently been shown to be efficacious in patients with PNH. This article reports on a 43-year-old female patient with PNH who was successfully treated with iptacopan. The patient had received ravulizumab for several years and developed a clinically relevant EVH. After obtaining informed consent, the patient received oral iptacopan 200 mg twice daily and ravulizumab was discontinued. Over the next few weeks hemoglobin levels and reticulocyte counts normalized. The patient reported mild flushes with erythema, chills, and mild muscle pain, all of which resolved during follow-up. No breakthrough hemolysis occurred, and no severe adverse events were recorded.
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria

Bo Xu,Bo Kang,Jixiang Chen,Shaoqian Li,Jiecan Zhou

DOI: https://doi.org/10.1016/j.blre.2024.101210

Abstract:Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, clonal, complement-mediated hemolytic anemia with a variety of manifestations. Currently, the methods for treating PNH include anti-C5 treatments (eculizumab and ravulizumab) and pegcetacoplan (a targeted C3 inhibitor). On December 5, 2023, the US FDA approved a factor B inhibitor called Fabhalta® (iptacopan), previously known as LNP023, for the treatment of adult patients with PNH, including those who have previously received anti-C5 therapy. The main objective of this review was to elucidate the clinical efficacy and safety of the newly approved factor B inhibitor, iptacopan. Iptacopan plays a proximal role in the alternative complement pathway to control extravascular hemolysis mediated by C3b and intravascular hemolysis mediated by terminal complement. The recommended dosage is 200 mg orally twice daily. The 24-week results of the pivotal phase III open-label trial, APPLY-PNH, demonstrated that among PNH patients who had previously received anti-C5 therapy, 51/60 (estimated percentages 82%) of patients in the iptacopan group showed an increase in hemoglobin of ≥2 g/dL compared to 0/35 (estimated percentages 2%) in the standard treatment group, also, 69% of iptacopan-treated patients achieved hemoglobin levels ≥12 g/dL, while no patients in the standard treatment group reached this level (both p < 0.001). The 48-week results were similar to those observed at 24 weeks. The most common adverse events were headache, infection and diarrhea. There were almost no clinical breakthrough hemolysis. Trials evaluating the long-term safety and efficacy of iptacopan are currently recruiting.
Iptacopan: First Approval

Yahiya Y. Syed

DOI: https://doi.org/10.1007/s40265-024-02009-4

2024-03-23

Drugs

Abstract:Iptacopan (FABHALTA ® ) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatment of complement-mediated diseases. Acting upstream of complement 5 in the alternative pathway, iptacopan inhibits both terminal complement-mediated intravascular haemolysis and complement 3-mediated extravascular haemolysis. On 5 December 2023, iptacopan received approval in the USA for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH). This article summarizes the milestones in the development of iptacopan leading to this first approval for PNH.

pharmacology & pharmacy,toxicology
MDS-278 Substantial Increases in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size with Oral Iptacopan Monotherapy Confirms Control of Hemolysis in Complement Inhibitor-Naive PNH Patients

Regis Peffault de Latour,Bing Han,Jaroslaw Maciejewski,Yasutaka Ueda,Rong Fu,Li Zhang,Austin Kulasekararaj,Alexander Roeth,Lee Ping Chew,Jun Ho Jang,Lee,Jens Panse,Eng-Soo Yap,Luana Marano,Flore Sicre de Fontbrune,Chen Yang,Partha Banerjee,Zhixin Wang,Christine Thorburn,Shujie Li,Marion Dahlke,Antonio Risitano

DOI: https://doi.org/10.1016/s2152-2650(23)01178-3

2023-01-01

Abstract:Context: Patients with hematological malignancies require regular Hb measurements as part of clinical monitoring.However, a laboratory-based Hb check involves several aspects able to affect
Recurrent cerebral ischemic infarction in a patient with paroxysmal nocturnal hemoglobinuria

Gaoping Lin,Wanzhuo Xie,Xiaobiao Lai

2012-01-01

Abstract:Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired stem cell disorder, leading to a deficient biosynthesis of GPI-linked proteins in hematopoetic cells. We report a 50-year-old female patient who presented with intravascular hemolysis, cytopenias, and recurrent thrombosis. This case documents a rare neurologic presentation of PNH with recurrent ischemic cerebral infarction.
Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis

Emir Muvaffak,Muhammed Edib Mokresh,Abdullah Varda,Mahmoud Lakmoush,Merve Kabasakal Ilter

DOI: https://doi.org/10.1080/17474086.2024.2422558

2024-10-29

Expert Review of Hematology

Abstract:Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by complement-mediated intravascular hemolysis (IVH). Current treatments like Eculizumab and Ravulizumab have limitations, with many patients still requiring transfusions. This study aimed to investigate the safety and efficacy of the new emergent treatment called Danicopan.

hematology
Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria

Bo Xu,Jiecan Zhou

DOI: https://doi.org/10.1080/17512433.2024.2403638

2024-09-21

Expert Review of Clinical Pharmacology

Abstract:Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder characterized by episodic hemolysis, with additional clinical manifestations including thrombosis and bone marrow failure. The US FDA approved a complement factor D inhibitor, danicopan (VoydeyaTM), previously known as ACH-4471, for the treatment of extravascular hemolysis in adults with PNH on 29 March 2024. The primary purpose of this review is to examine the clinical efficacy and safety of danicopan.

pharmacology & pharmacy
P839: Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Pegcetacoplan Show Improvements In D-Dimer Normalization And Decrease In Incidence Of Thrombosis

I. Weitz,M. Al-Adhami,J. Min,E. Persson,M. Yeh,J. Savage,D. Dingli

DOI: https://doi.org/10.1097/01.hs9.0000846240.50953.6f

2022-06-25

HemaSphere

Abstract:Background: Thrombosis is the main life-threatening complication of paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hematologic disease. Pegcetacoplan (PEG) is a C3 complement-inhibitor approved by the FDA/EMA for treatment of adults with PNH.
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria

Ryan L. Crass,Brandon Smith,Sven Adriaens,Sunny Chapel,Grant Langdon

DOI: https://doi.org/10.1007/s40268-024-00500-7

2024-11-30

Drugs in R&D

Abstract:Paroxysmal nocturnal hemoglobinuria is a rare blood disorder characterized by life-threatening hemolysis and thrombosis. Complement C5 inhibitor therapy improves symptoms and life prognosis; however, it can result in insufficient hemolysis control, with residual intravascular hemolysis and extravascular hemolysis in some patients. Pegcetacoplan, the first complement C3 inhibitor approved for patients with paroxysmal nocturnal hemoglobinuria, targets both intravascular and extravascular hemolysis. This analysis evaluated population pharmacokinetic/pharmacodynamic profiles of pegcetacoplan.

pharmacology & pharmacy
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study

Christopher J. Patriquin,Andrija Bogdanovic,Morag Griffin,Richard J. Kelly,Jaroslaw P. Maciejewski,Brian Mulherin,Régis Peffault de Latour,Alexander Röth,Veena Selvaratnam,Jeffrey Szer,Mohammed Al-Adhami,Regina Horneff,Lisa Tan,Michael Yeh,Jens Panse

DOI: https://doi.org/10.1007/s12325-024-02827-8

2024-04-05

Advances in Therapy

Abstract:Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening disease characterized by complement-mediated hemolysis and thrombosis. Pegcetacoplan, the first targeted complement component 3 (C3) PNH therapy, was safe and efficacious in treatment-naive and pre-treated patients with PNH in five clinical trials.

pharmacology & pharmacy,medicine, research & experimental
First Successful Treatment of a Patient with a Primary Immune Complex-Membranoproliferative Glomerulonephritis with Iptacopan: A Case Report

Simone Arnold,Manuela Nickler,Michael Dickenmann,Thomas Menter,Helmut Hopfer,Patricia Hirt-Minkowski

DOI: https://doi.org/10.1159/000540013

2024-08-07

Abstract:Introduction: Nowadays, there is insufficient evidence for the recommendation of management patients with a primary membranoproliferative glomerulonephritis (MPGN). A better understanding of the pathogenesis has led to the reclassification of primary MPGN and distinction into the two main entities of either primary immune complex-MPGN or C3 glomerulopathy. Both entities share overlapping pathophysiological features with complement alternative pathway (AP) dysregulation. Iptacopan is an oral inhibitor of the complement factor B that effectively blocks the complement AP. Case presentation: We report the first successful treatment of a 47-year-old man suffering from a primary immune complex-MPGN with iptacopan. So far established immunosuppressive therapies with prednisone and mycophenolate mofetil failed to control the current flare of the disease, mainly presenting with impaired kidney function and proteinuria within the nephrotic range. However, 3 months after starting the treatment with iptacopan urine protein-creatinine ratio decreased impressively to a level of 100-150 mg/mmol. Thereafter, low-level proteinuria and kidney function remained stable during follow-up. Do date, the treatment with iptacopan is continued as a monotherapy and is well tolerated. Conclusion: To the best of our knowledge, this is the first case report which suggests that iptacopan may be an interesting treatment option for primary immune complex-MPGN.
Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria

Tze Wei Chan,Hein Than,Tertius Tuy,Yeow Tee Goh

DOI: https://doi.org/10.1080/17474086.2024.2440101

2024-12-18

Expert Review of Hematology

Abstract:Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder of hematopoietic stem cells, characterized by somatic mutations of the Phosphatidylinositol Glycan Class A Gene, resulting in increased hemolysis. The advent of complement inhibitors has since changed the way clinicians approach treating PNH. Pegcetacoplan is a C3 inhibitor that has shown promise in this field and improved outcomes for patients who have been diagnosed with PNH.

hematology
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy

Vlado Perkovic,Jonathan Barratt,Brad Rovin,Naoki Kashihara,Bart Maes,Hong Zhang,Hernán Trimarchi,Dmitrij Kollins,Olympia Papachristofi,Severina Jacinto-Sanders,Tobias Merkel,Nicolas Guerard,Ronny Renfurm,Thomas Hach,Dana V Rizk

DOI: https://doi.org/10.1056/NEJMoa2410316

2024-10-25

Abstract:Background: The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. Methods: In this phase 3, double-blind, randomized, placebo-controlled trial, we enrolled adults with biopsy-confirmed IgA nephropathy and proteinuria (defined as a 24-hour urinary protein-to-creatinine ratio of ≥1 [with protein and creatinine both measured in grams]) despite optimized supportive therapy. Patients were randomly assigned, in a 1:1 ratio, to receive oral iptacopan (200 mg) or placebo twice daily for 24 months while continuing to receive supportive therapy. The primary objective of this prespecified interim analysis was to assess the efficacy of iptacopan as compared with that of placebo in reducing proteinuria at month 9; the primary end point was the change from baseline in the 24-hour urinary protein-to-creatinine ratio at month 9. The proportion of patients who had a 24-hour urinary protein-to-creatinine ratio of less than 1 at month 9 without receiving rescue or alternative medication or undergoing kidney-replacement therapy (dialysis or transplantation) was a secondary end point. Safety was also assessed. The effect of iptacopan on kidney function will be assessed at the end of the 2-year double-blind treatment period. Results: The main trial population included 222 patients in the iptacopan group and 221 in the placebo group. The interim efficacy analysis included the first 250 patients who underwent randomization in the main trial population (125 patients in each group) and who remained in the trial until month 9 or discontinued the trial by month 9. Safety was assessed in all the patients in the main trial population. At month 9, the adjusted geometric mean 24-hour urinary protein-to-creatinine ratio was 38.3% (95% confidence interval, 26.0 to 48.6; two-sided P<0.001) lower with iptacopan than with placebo. The reduction in proteinuria was supported by consistent results in secondary end point analyses. There were no unexpected safety findings with iptacopan. The incidence of adverse events that occurred during the treatment period was similar in the two groups; most events were mild to moderate in severity and reversible. No increased risk of infection was observed. Conclusions: Among patients with IgA nephropathy, treatment with iptacopan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, NCT04578834.).
Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials

Vanda P. Peixoto,Cristina Prudêncio,Mónica Vieira

DOI: https://doi.org/10.1080/03007995.2024.2354533

2024-05-18

Current Medical Research and Opinion

Abstract:Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disease in which blood cells lack anchored proteins that regulate the complement system. The erythrocytes are then destroyed because of uncontrolled complement activity, leading to intravascular hemolysis (IVH) and a high risk of thrombosis outcome. A huge alteration in the treatment of the disease was the development of terminal complement inhibitors, with the achievement of IVH blockade, reduction or abolishment of red blood cell (RBC) transfusions, and thromboembolic events prevention. However, patients treated with these inhibitors can still present extravascular hemolysis (EVH) caused by C3 activation and residual IVH or clinically relevant levels of breakthrough hemolysis (BTH). Proximal complement inhibitors turned out to be the key to the solution of this problem by targeting components of the proximal complement pathway, avoiding intra and extravascular hemolysis. FDA approved eculizumab, ravulizumab (terminal inhibitors), pegcetacoplan, iptacopan, and danicopan (proximal inhibitors) as a treatment for PNH so far. Various clinical trials are underway to find the most effective method to treat patients with PNH. This review aimed to summarize 71 registered clinical trials in the ClinicalTrials.gov database with the various treatment drugs, possible mechanisms, and novel findings related to PNH treatment.

medicine, general & internal, research & experimental
Peptide Inhibitors of C3 Activation As a Novel Strategy of Complement Inhibition for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Antonio M. Risitano,Daniel Ricklin,Yijun Huang,Edimara S. Reis,Hui Chen,Patrizia Ricci,Zhuoer Lin,Caterina Pascariello,Maddalena Raia,Michela Sica,Luigi Del Vecchio,Fabrizio Pane,Florea Lupu,Rosario Notaro,Ranillo R. G. Resuello,Robert A. DeAngelis,John D. Lambris

DOI: https://doi.org/10.1182/blood-2013-11-536573

IF: 20.3

2014-01-01

Blood

Abstract:Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated intravascular hemolysis due to the lack of CD55 and CD59 on affected erythrocytes. The anti-C5 antibody eculizumab has proven clinically effective, but uncontrolled C3 activation due to CD55 absence may result in opsonization of erythrocytes, possibly leading to clinically meaningful extravascular hemolysis. We investigated the effect of the peptidic C3 inhibitor, compstatin Cp40, and its long-acting form (polyethylene glycol [PEG]-Cp40) on hemolysis and opsonization of PNH erythrocytes in an established in vitro system. Both compounds demonstrated dose-dependent inhibition of hemolysis with IC50 ∼4 µM and full inhibition at 6 µM. Protective levels of either Cp40 or PEG-Cp40 also efficiently prevented deposition of C3 fragments on PNH erythrocytes. We further explored the potential of both inhibitors for systemic administration and performed pharmacokinetic evaluation in nonhuman primates. A single intravenous injection of PEG-Cp40 resulted in a prolonged elimination half-life of >5 days but may potentially affect the plasma levels of C3. Despite faster elimination kinetics, saturating inhibitor concentration could be reached with unmodified Cp40 through repetitive subcutaneous administration. In conclusion, peptide inhibitors of C3 activation effectively prevent hemolysis and C3 opsonization of PNH erythrocytes, and are excellent, and potentially cost-effective, candidates for further clinical investigation.
Use of Intravenous Immunoglobulin in the Treatment of Paroxysmal Nocturnal Hemoglobinuria : a Case Report and Literature Review

Ying Shen,Fangxia Wang,Yun Yang,Wanggang Zhang,Aili He

2018-01-01

Abstract:Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder of hematopoietic stem cell (HSC) that makes blood cells more sensitive to active complement system. Eculizumab is considered as primary treatment for PNH nowadays. Because of the commercial unavailability of eculizumab in China, the treatment is still at a conventional level, such as using steroid and blood transfusion. However, PNH treated with intravenous immunoglobulin (IVIG) has never been reported. Here, we reported a patient treated with IVIG and got better therapeutic effects, presenting with obviously improved hemoglobin and dropped lactate dehydrogenase (LDH) close to normal level after IVIG. We think IVIG for PNH is worth being concerned and verified as an alternative therapy when eculizumab is not in hand.

Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria

Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria

Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria

Iptacopan Efficacy and Safety to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta-Analysis

Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH)

Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria

Iptacopan: First Approval

MDS-278 Substantial Increases in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell Clone Size with Oral Iptacopan Monotherapy Confirms Control of Hemolysis in Complement Inhibitor-Naive PNH Patients

Recurrent cerebral ischemic infarction in a patient with paroxysmal nocturnal hemoglobinuria

Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis

Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria

P839: Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Pegcetacoplan Show Improvements In D-Dimer Normalization And Decrease In Incidence Of Thrombosis

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria

Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study

First Successful Treatment of a Patient with a Primary Immune Complex-Membranoproliferative Glomerulonephritis with Iptacopan: A Case Report

Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria

Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy

Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials

Peptide Inhibitors of C3 Activation As a Novel Strategy of Complement Inhibition for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Use of Intravenous Immunoglobulin in the Treatment of Paroxysmal Nocturnal Hemoglobinuria : a Case Report and Literature Review